Latest news and press releases about AEON Biopharma, Inc. (AEON): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc.
Price
| Price | $0.26 |
| Market Cap | $11M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | -0.85 |
| EV / EBITDA | -0.54 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 204.18% |
| Return on Invested Capital | 1699.74% |
| Return on Assets | -924.25% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABP · APM · BOLT · CING · CLNN · CLRB · LYRA
Explore sector: Healthcare · Biotechnology
More sections of AEON: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks